The findings could be an important step toward personalized medicine for women with the disease, said UCLA’s Dr. Patricia Ganz.
Other diagnostic tools may be more efficient and cost-effective for the general population, although genetic screening remains valuable for women in groups known to carry certain genetic mutations.
Elisa Long, an expert in probability and statistics at the UCLA Anderson School of Management, wrote a column that appeared in the Washington Post about how statistics helped guide her through life, death and 'The Price is Right.'
Breast cancer treatment with fewer potential side effects has equally good patient outcomes, UCLA study shows
Newer, more targeted method, called partial breast irradiation, takes less time to complete and is less likely to expose vital organs to potentially harmful radiation.
Revlon CEO Lorenzo Delpani, chairman Ronald O. Perelman and global brand ambassador Halle Berry announced the gift at an event honoring Slamon, a member of the UCLA Jonsson Comprehensive Cancer Center.
The researchers say that women with a high risk for breast cancer recurrence benefit by having chemotherapy as part of their treatment, but for those at low risk, chemo has no added value.
The team, led by Dr. Joanne Weidhaas, found that acute estrogen withdrawal was associated with breast cancer in women with the KRAS-variant.
Wealthier women living in communities with larger income gaps are most likely to get a test that can help determine the best way to treat early-stage breast cancer.
A series of mental training exercises has been shown to help mitigate the effects of “chemo brain,” which affects up to 35 percent of women after their treatments for breast cancer.
UCLA cancer research pioneer works with Apple on mobile app to track breast cancer survivors’ experiences
On March 9, Apple announced the launch of Share the Journey, a mobile app that UCLA’s Dr. Patricia Ganz helped develop.
UCLA bioengineers have developed a revolutionary approach that brings together traditional drugs and nanotechnology-enhanced medications to create safer and more effective treatments.
Research at UCLA played key role in developing the treatment, which could signal a new strategy for arresting tumor growth and extending the time before cancer worsens.
UCLA study shows that combining palbociclib with letrozole effectively doubled the length of time women with estrogen receptor-positive breast cancer were on treatment without their cancer worsening.
Researchers suggest that practicing the ancient Chinese martial art could potentially lower the risk for cancer recurrence and other chronic diseases in cancer survivors.
For women with advanced breast cancer who took the experimental drug palbociclib, the amount of time patients were on treatment without their cancer worsening was effectively doubled.